Nuvation Bio clinical trials we track

Check company identity source

Phase 3 3 trials

Phase 2 4 trials

Drugs in these trials

Names as written in the registry records.

Latest recorded trial changes

Filters
Clear filters

· 4 fields changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Part 1: Incidence of adverse events (AEs) and serious adverse events (SAEs) Measure: Part 2: Progression-free survival (PFS) assessed by Blinded Independent Central Review (BICR) per Response Assessment in Neuro-Oncology (RANO) 2.0. After: Measure: Part 1: Incidence of adverse events (AEs) and serious adverse events (SAEs) Measure: Part 2: Progression-free survival (PFS) assessed by Blinded Independent Central Review (BICR) per Response Assessment in Neuro-Oncology (RANO) 2.0 Measure: Part 3 Objective Response Rate (ORR) (Complete Response (CR), Partial Response (PR) and Minor Response (MR)) assessed by Blinded Independent Central Review (BICR) per Response Assessment in Neuro-Oncology (RANO) 2.0.

Planned enrollment increased by 240 participants

Before: 125 participants (planned). After: 365 participants (planned).

Primary completion date changed

Before: 1 Dec 2027. After: 1 Dec 2028.

Phase changed

Before: PHASE2. After: PHASE3.

Check registry source

· 6 fields changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Best overall response (BOR). After: Measure: Objective response rate (ORR).

Participant count type changed

Before: Estimated. After: Actual.

Enrollment · participant count changed

Before: 40 participants (planned). After: 14 participants (actual).

Completion date type changed

Before: Estimated. After: Actual.

Primary completion date changed

Before: 30 Apr 2024. After: 6 Dec 2024.

Recruitment status changed

Before: Recruiting. After: Terminated.

Check registry source